The IND clearance is a near-term positive catalyst but expected for a clinical-stage biotech. Traders should watch for enrollment updates and any early safety/efficacy signals from the Phase 1/2a trial. Given the tiny $8M market cap, the stock is highly volatile and binary events could cause sharp moves.
Price Chart
Executive Summary
BriaCell received FDA clearance of its Investigational New Drug (IND) application for Bria-PROS+, a next-generation personalized immunotherapy for prostate cancer, allowing initiation of a Phase 1/2a clinical study. This is a positive regulatory milestone for the company's pipeline but does not yet change fundamental valuation as the therapy remains early-stage and pre-revenue.
Key Facts
- FDA issued a 'Study May Proceed' letter for Bria-PROS+, clearing the IND for clinical evaluation.
- Bria-PROS+ is a next-generation personalized, off-the-shelf, cell-based immunotherapy for prostate cancer.
- The program was previously awarded a $2 million non-dilutive grant from the US National Cancer Institute in August 2025.
- BriaCell plans to initiate a Phase 1/2a clinical study following this clearance.
Financial Impact
No immediate financial impact; clinical-stage with no revenue.
Risk Factors
- Early-stage clinical risk: Bria-PROS+ has not demonstrated efficacy in humans.
- Tiny market cap ($8M) makes the stock highly speculative and prone to large swings.
- Need for additional capital to fund trials beyond the $2M NCI grant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339216 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers